BioCryst halts leukemia trial

BioCryst has discontinued a Phase IIb trial of intravenous Forodesine HCl in patients with T-cell acute lymphoblastic leukemia/lymphoma. The decision to discontinue the trial was based on a number of issues. There were delays associated with addressing a previously announced stability problem, a limited number of patients were eligible to be enrolled in the trial and, to cap it all off, there was a lower-than-expected response rate observed in an earlier trial. BioCryst made sure to point out that other clinical trials, which are using the oral capsule formulation of forodesine HCl, are still ongoing.

- see BioCryst's release for more

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.